Not good.
Additional phase 3 VSV-EBOV trial findings based on participants in earlier studies in the United States, Canada, and Spain found that immunogenicity was durable and persisted through 24 months and that doses from three different vaccine lots showed similar immunogenicity at 28 days.
Better. No fatalities from the vaccine, which is better still, and not that easy to do with a disease like Ebola. This is a race, all right.
When I saw “DRC” I immediately thought of The Democratic Republic of California where they’re having a bit of Ebola.
Still “The Heart of Darkness.”